Long-term Safety, Tolerability and Efficacy of BAF312 Given Orally in Patients With Relapsing-remitting Multiple Sclerosis
Clinical trial NCT01185821 · COMPLETED
Trial details
- NCT number
- NCT01185821
- Sponsor
- Novartis Pharmaceuticals
- Status
- COMPLETED
- Phase
- Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2010-08-30
- Primary completion
- 2016-10-10
- Enrollment
- 185
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.